{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:25:42Z","timestamp":1794097542227,"version":"4.8.0"},"reference-count":134,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Natural treatments may be used as an alternative or adjunct treatment for childhood neuropsychiatric disorders. Knowledge of benefits and harms is needed to inform use guidelines. We aimed to systematically identify how and which adverse events are monitored, assessed, and reported in pediatric trials that tested nutraceutical and phytoceutical treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched MEDLINE, Embase, PsycINFO, ProQuest Dissertations and Theses Global, Cochrane Library, and Google Scholar from 2012 to 2024. Eligible studies included nutraceutical and phytoceutical trials, experimental or quasi-experimental in design, involving children or adolescents (age 4\u201319\u2009years) with neuropsychiatric conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ninety-eight trials were included with 75 reported as completed (77%). The most common natural treatment tested was polyunsaturated fatty acids (36%, 35\/98). Most trials focused on treating attention-deficit\/hyperactivity disorder (59%, 58\/98) or autism spectrum disorder (21%, 21\/98). Investigators from 74\/98 trials (76%) reported methods that indicated adverse event monitoring. For these trials, events defined a priori for monitoring were identified in 43% (32\/74), methods for collecting and recording events were described in 68% (50\/74), and assessment of event severity and attribution was described in 49% (36\/74) and 26% (19\/74), respectively. Over 100 different adverse events were reported across completed trials. The most common events reported were gastrointestinal distress (65%, 49\/75) and headache (33%, 25\/75).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>We found variability in monitoring, assessing, and reporting adverse events in pediatric trials of natural treatments. The adverse events identified in this review reinforces that specific events should be prospectively monitored in future trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251344683","type":"journal-article","created":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T09:23:53Z","timestamp":1752398633000},"page":"1232-1244","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Adverse event monitoring, assessment, and reporting in nutraceutical and phytoceutical trials for pediatric neuropsychiatric conditions: A systematic review"],"prefix":"10.1177","volume":"39","author":[{"given":"Kalee","family":"Lodewyk","sequence":"first","affiliation":[{"name":"Edmonton Clinic Health Academy, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren B","family":"Courtney","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Bagnell","sequence":"additional","affiliation":[{"name":"IWK Health, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3020-674X","authenticated-orcid":false,"given":"Amanda S","family":"Newton","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Edmonton Clinic Health Academy, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2018.12.002"},{"key":"e_1_3_2_3_1","unstructured":"Agency for Healthcare Research and Quality (2019) Adverse events near misses and errors. Available at: https:\/\/psnet.ahrq.gov\/primer\/adverse-events-near-misses-and-errors (accessed 19 October 2024)."},{"key":"e_1_3_2_4_1","article-title":"Eliciting adverse effects data from participants in clinical trials","volume":"1","author":"Allen EN","year":"2018","unstructured":"Allen EN, Chandler CI, Mandimika N, et al. (2018) Eliciting adverse effects data from participants in clinical trials. Cochrane Database Syst Rev 1: MR000039.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_5_1","article-title":"Effect of polyunsaturated fatty acids administration on children with attention deficit hyperactivity disorder: A randomized controlled trial","volume":"10","author":"Anand P","year":"2016","unstructured":"Anand P, Sachdeva A (2016) Effect of polyunsaturated fatty acids administration on children with attention deficit hyperactivity disorder: A randomized controlled trial. J Clin Diagn Res 10: OC01\u2013OC05.","journal-title":"J Clin Diagn Res"},{"key":"e_1_3_2_6_1","unstructured":"American Academy of Pediatrics and National Initiative for Children\u2019s Healthcare Quality (NICHQ) (2002) NICHQ Vanderbilt assessment follow-up. Available at: https:\/\/www.aacap.org\/App_Themes\/AACAP\/docs\/member_resources\/toolbox_for_clinical_practice_and_outcomes\/symptoms\/NICHQ_Vanderbilt_Assessment_Follow_Up-PARENT-Informant.pdf (accessed 24 March 2025)."},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2016.0261"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054712463962"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054713518239"},{"key":"e_1_3_2_10_1","unstructured":"Barkley RA (1981) Hyperactive Children: A Handbook for Parents. New York NY: Guildford Press. Available at: https:\/\/www.asmajsadiq.com\/storage\/app\/media\/9-side-effect-rating-scale.pdf (accessed 26 March 2025)."},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10578-020-01072-8"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0146"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2014.01.018"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14194046"},{"key":"e_1_3_2_15_1","unstructured":"Bloch MH (2022) A clinical study to evaluate the safety and efficacy of T92 in pediatric patients with Tourette Syndrome. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05188274 (accessed 19 October 2024)."},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.73"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2020.05.005"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/advances\/nmab088"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-022-01428-2"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0633-0"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-4082"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.06.007"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.02.013"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-017-1058-z"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-018-1223-z"},{"key":"e_1_3_2_26_1","first-page":"7","article-title":"Comparison of therapeutic effects of omega-3 and methylphenidate (Ritalin\u00ae) in treating children with attention deficit hyperactivity disorder","volume":"8","author":"Dashti N","year":"2014","unstructured":"Dashti N, Hekmat H, Soltani HR, et al. (2014) Comparison of therapeutic effects of omega-3 and methylphenidate (Ritalin\u00ae) in treating children with attention deficit hyperactivity disorder. Iran J Psychiatry Behav Sci 8: 7\u201311.","journal-title":"Iran J Psychiatry Behav Sci"},{"key":"e_1_3_2_27_1","unstructured":"Davies PSW (2023) Combined human milk oligosaccharides (HMOs) and probiotics intervention for children with autism. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05151601 (accessed 19 October 2024)."},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2013.0093"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.5114\/pedm.2020.101806"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2014.00780"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-05324-4"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13750-022-00264-0"},{"key":"e_1_3_2_33_1","unstructured":"Feng Y (2024) A randomized double-blind carbon water controlled single center evaluation of the improvement and tolerability of high protein beverages supplemented with walnut peptide and phosphatidylserine in Chinese children with attention deficit disorder aged 6. Available at: https:\/\/www.chictr.org.cn\/showproj.html?proj=205611 (accessed 19 October 2024)."},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1637-7"},{"key":"e_1_3_2_35_1","unstructured":"Ford T (2023) Effects of cannabidiol in children with autism. Available at: https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12622000437763 (accessed 19 October 2024)."},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/15374416.2016.1233500"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0132"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.04.039"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11596"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-3384"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0157"},{"key":"e_1_3_2_42_1","first-page":"108","article-title":"Effect of methylphenidate and folic acid on ADHD symptoms and quality of life and aggression: A randomized double-blind placebo controlled clinical trial","volume":"8","author":"Ghanizadeh A","year":"2013","unstructured":"Ghanizadeh A, Sayyari Z, Mohammadi M-R (2013) Effect of methylphenidate and folic acid on ADHD symptoms and quality of life and aggression: A randomized double-blind placebo controlled clinical trial. Iran J Psychiatry 8: 108\u2013112.","journal-title":"Iran J Psychiatry"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.62.1.23"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06297-7"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000142668.29191.13"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/erv.2876"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06802-y"},{"key":"e_1_3_2_48_1","unstructured":"Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Rockville MD: United States Department of Health Education and Welfare. Available at: https:\/\/ia800200.us.archive.org\/19\/items\/ecdeuassessmentm1933guyw\/ecdeuassessmentm1933guyw.pdf (accessed 25 March 2025)."},{"key":"e_1_3_2_49_1","unstructured":"Gyrgo M (2014) Supplementation of polyunsaturated fatty acids in children with attention deficit\/hyperactivity disorder (ADHD). Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02114632 (accessed 19 October 2024)."},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00863"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/1028415X.2019.1588486"},{"key":"e_1_3_2_52_1","first-page":"329","article-title":"Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder","volume":"18","author":"Hariri M","year":"2012","unstructured":"Hariri M, Djazayery A, Djalali M, et al. (2012) Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. Malays J Nutr 18: 329\u2013335.","journal-title":"Malays J Nutr"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10578-012-0292-3"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2023.11.010"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-021-02631-1"},{"key":"e_1_3_2_56_1","first-page":"1","article-title":"Effect of vitamin D and magnesium supplementation on behavior problems in children with attention-deficit hyperactivity disorder","volume":"11","author":"Hemamy M","year":"2020","unstructured":"Hemamy M, Heidari-Beni M, Askari G, et al. (2020) Effect of vitamin D and magnesium supplementation on behavior problems in children with attention-deficit hyperactivity disorder. Int J Prevent Med 11: 1\u20136.","journal-title":"Int J Prevent Med"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13076"},{"key":"e_1_3_2_58_1","first-page":"210","article-title":"Evaluation of the effectiveness of Withania somnifera root extract on the anxiety symptoms among children with ADHD in Mashhad","volume":"13","author":"Hosseini M","year":"2019","unstructured":"Hosseini M, Moharahi F, Soltanifar A, et al. (2019) Evaluation of the effectiveness of Withania somnifera root extract on the anxiety symptoms among children with ADHD in Mashhad. Pakist J Med Health Sci 13: 210\u2013216.","journal-title":"Pakist J Med Health Sci"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115098"},{"key":"e_1_3_2_60_1","unstructured":"International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) (n.d.) Medical dictionary for regulatory activities. Available at: https:\/\/www.meddra.org (accessed 19 October 2024)."},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.313"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-10-200411160-00009"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1238973"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2021.07.005"},{"key":"e_1_3_2_65_1","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: Updated guideline for the reporting of harms in randomized trials","volume":"381","author":"Junqueira DR","year":"2022","unstructured":"Junqueira DR, Zorzela L, Golder S, et al. (2022) CONSORT Harms 2022 statement, explanation, and elaboration: Updated guideline for the reporting of harms in randomized trials. Br Med J 381: e073725.","journal-title":"Br Med J"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu7125507"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4471-y"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06413-7"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.5812\/ijpbs.108390"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2018.04.022"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00181"},{"key":"e_1_3_2_72_1","unstructured":"Kvernmo S (2024) Intervention with omega-3 in children with attention deficit hyperactivity disorder (ADHD). Available at: https:\/\/clinicaltrials.gov\/study\/NCT02986672 (accessed 19 October 2024)."},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-071063"},{"key":"e_1_3_2_74_1","unstructured":"Lawrence K (2023) Probiotic supplementation in children with ADHD. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05155696 (accessed 19 October 2024)."},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3537-7"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2019.0041"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu11040820"},{"key":"e_1_3_2_78_1","unstructured":"Llevadot JS (2019) Superiority of omega-3 versus placebo on the improvement of ADHD in children (ECOMEGA). Available at: https:\/\/clinicaltrials.gov\/study\/NCT02248948 (accessed 19 October 2024)."},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098611401129"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2011.05.004"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0029665117002026"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12979"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2011.12.009"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/1028415X.2023.2233752"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/1028415X.2016.1262097"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2018.06982"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13016"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/20473869.2018.1502068"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.31661\/gmj.v9i.1690"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctcp.2019.07.008"},{"key":"e_1_3_2_91_1","unstructured":"Murdoch Children\u2019s Research Institute (2024) Is medicinal cannabis an effective treatment for Tourette syndrome in adolescents? A pilot study. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05184478 (accessed 19 October 2024)."},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eujim.2018.10.006"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-10-200405180-00009"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu15061351"},{"key":"e_1_3_2_95_1","unstructured":"Ni HC (2023) Effects of Lactobacillus Plantarum PS128 in children with ASD. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05307744 (accessed 19 October 2024)."},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000063"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2019.101868"},{"key":"e_1_3_2_98_1","first-page":"73","article-title":"The efficacy of magnesium supplementation in children with attention deficit hyperactivity disorder under treatment with methylphenidate: A randomized controlled trial","volume":"8","author":"Noorazar SG","year":"2021","unstructured":"Noorazar SG, Kalejahi P, Setayesh S, et al. (2021) The efficacy of magnesium supplementation in children with attention deficit hyperactivity disorder under treatment with methylphenidate: A randomized controlled trial. Crescent J Med Biol Sci 8: 73\u201376.","journal-title":"Crescent J Med Biol Sci"},{"key":"e_1_3_2_99_1","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Br Med J 372: n71.","journal-title":"Br Med J"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-024-06239-z"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.4103\/japtr.JAPTR_45_17"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14214637"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073811435243"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1097\/DBP.0000000000000993"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/apa.13108"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.34172\/aim.2022.47"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291718000983"},{"key":"e_1_3_2_108_1","unstructured":"Reynolds WM (1987) Suicidal Ideation Questionnaire (SIQ-JR) Professional Manual. Odessa FL: Psychological Assessment Resources. Available at: https:\/\/www.parinc.com\/products\/siq (accessed 25 March 2025)."},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14040852"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12892"},{"key":"e_1_3_2_111_1","unstructured":"Rhoads JM (2024) Combination probiotic: BB-12 with LGG (different doses) in treating children with autism spectrum disorder. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03514784 (accessed 19 October 2024)."},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S206020"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12817"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.4103\/2279-042X.176561"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06837-1"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2021.2013041"},{"key":"e_1_3_2_117_1","unstructured":"Scahill L (2021) A feasibility study of N-acetylcysteine for self-injurious behavior in children with autism spectrum disorder. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03008889 (accessed 19 October 2024)."},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.4103\/iahs.iahs_112_20"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctcp.2015.04.001"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1177\/10870547221129307"},{"key":"e_1_3_2_121_1","unstructured":"Straussberg R (2014) Efficacy of combined treatment with CoQ10 and methylphenidate in children with attention deficit hyperactivity disorder. Available at: https:\/\/clinicaltrials.gov\/study\/NCT02315651 (accessed 19 October 2024)."},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2021.19.4.712"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.112911"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116658986"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.061960"},{"key":"e_1_3_2_126_1","unstructured":"U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER) (2018) E6(R2) Good Clinical Practice: Integrated addendum to ICH E6(R1) guidance for industry. Available at: https:\/\/www.fda.gov\/media\/93884\/download (accessed 19 October 2024)."},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1879-6"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2012.v6.4.212"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2014.04.004"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-016-0088-6"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2528"},{"key":"e_1_3_2_132_1","unstructured":"World Health Organization (2010) The conceptual framework for the international classification for patient safety. Available at: https:\/\/www.who.int\/publications\/i\/item\/WHO-IER-PSP-2010.2 (accessed 19 October 2024)."},{"key":"e_1_3_2_133_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09267"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu13113698"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050541"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251344683","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251344683","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251344683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:15Z","timestamp":1777507935000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251344683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,13]]},"references-count":134,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/02698811251344683"],"URL":"https:\/\/doi.org\/10.1177\/02698811251344683","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,13]]}}}